All Professionals
Overview
Chinmay Bagwe is an associate in the Intellectual Property practice of Paul Hastings and is based in the firm’s New York office. His practice focuses on IP litigation, including both life sciences and tech patent litigation. Chinmay has been a core member of trial and litigation teams that have successfully represented major pharmaceutical and tech companies in high-stakes cases in federal courts, including New Jersey and Delaware, and appeals before the Federal Circuit. At trials, Chinmay has prepared both fact and expert witnesses and second chaired direct and cross examinations. Prior to joining Paul Hastings, Chinmay was an associate at an IP boutique law firm in New York.
Accolades
- Mock Argument Advocate, Federal Circuit Bar Association Bench & Bar® Conference (2024)
- Atlas Award, Leadership Council on Legal Diversity, Pathfinder (2023)
- Excellence in Intellectual Property, UNH Franklin Pierce School of Law (2019)
Education
- UNH Franklin Pierce School of Law, J.D., IP Cert., 2019 (IP Redux Leader and Editor for IDEA®: The Law Review of the Franklin Pierce Center for IP, Vol. 59)
- NMIMS Institute of Intellectual Property Studies, IP Cert., 2016
- University of Mumbai, M.Sc., Biotech., 2015 (with First Class Honors)
Representations
- Inpria Corp. v. Lam Research Corp., No. 22-1359 (D. Del.). Represented Inpria in a patent litigation concerning Inpria’s metal oxide resist (MOR) technology for extreme ultraviolet light (EUV) lithography used in advanced semiconductor manufacturing. Following Inpria’s filing of a preliminary injunction motion, the litigation settled on favorable terms.
- Supernus Pharms. Inc. v. Torrent Pharms. Ltd. et al., Nos. 21-6964, 21-14268 (D.N.J.) (Trial Victory) Represented Supernus in a Hatch-Waxman trial against Torrent Pharma concerning Supernus’s multi-million dollar anti-epileptic drug Trokendi XR®. All of Supernus’s asserted claims across three Orange Book-listed patents were held infringed and valid.
- Takeda Pharm. Co. Ltd. et al. v. Norwich Pharms., Inc., No. 20-8966 (D.N.J.) (Trial Victory) aff’d, 23-1374 (Fed. Cir.) Represented Takeda in a Hatch-Waxman trial and appeal against Norwich concerning Takeda’s blockbuster ADHD drug Vyvanse®. All of Takeda’s asserted claims across nine Orange Book-listed patents were held infringed, not invalid, and enforceable.
- Astellas US LLC et al. v. Curia Missouri Inc. et al., No. 22-0199 (D. Del.) Represented Curia in a patent litigation against plaintiffs Astellas and Gilead concerning plaintiffs’ pharmacologic stress testing agent Lexiscan®. Plaintiffs voluntarily dismissed the case pending Curia’s case-dispositive motion to dismiss and in light of plaintiffs’ defeat at trial and on appeal in a related case: Astellas US LLC et al. v. Hospira, Inc., No. 18-1675 (D. Del.) (finding that Curia’s API and manufacturing process do not infringe the asserted patent claims) aff’d, 22-1878 (Fed. Cir.).
- AbbVie Endocrine Inc. v. Takeda Pharm. Co. Ltd., No. 20-0953 (Del. Ch.) (Injunction Trial Victory) Represented Takeda in the injunction phase of a trial arising from a breach of contract dispute against AbbVie concerning AbbVie’s endometriosis and prostate cancer treatment Lupron Depot®. AbbVie’s request for expedited injunctive relief was denied.
*Matters may have been handled prior to joining Paul Hastings.
Engagement & Publications
PUBLICATIONS
- "Purdue v. Collegium: Upholding the Board’s Authority to Issue a Final Written Decision Even After the Statutory Deadline Has Passed", JD Supra, Co-author (December 1, 2023)
- "Google v. Hammond: IPR and Collateral Estoppel", JD Supra, Co-author (January 5, 2023)
- "A Word of Caution When Disclosing Confidential Information to a Non-Party Under a Protective Order", JD Supra, Co-author (July 15, 2022)
- "AstraZeneca AB v. Mylan Pharms. Inc.: Claim Construction of a Percentage Term Guided by the Written Description and Prosecution History", JD Supra, Co-author (January 3, 2022)
- "Minerva v. Hologic: Assignor Estoppel Doctrine Retained, but Limited", JD Supra, Co-author (July 20, 2021)
- "Meet and Confer Requirements Added for Rule 30(b)(6) Depositions", JD Supra, Co-author (January 15, 2021)
- "Venue in Hatch-Waxman Litigation: What Courts Decided and What Litigants Are Still Fighting Over", JD Supra, Co-author (December 8, 2020)
Involvement
- Judicial intern – The Honorable Jimmie V. Reyna of the United States Court of Appeals for the Federal Circuit
- Member – Federal Circuit Bar Association
- Member – Leadership Council on Legal Diversity